Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion, or $34 per share.
Estimates for erenumab annual sales run as high as $2.3 billion.
Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion and the biosimilars unit of German peer Merck KGaA.
Bard was shopped to BD as an acquisition target about 15 years ago
The New Brunswick, N.J.-based company noted that its pharma sales dipped due to weakness in the U.S. compared to other markets.
New drug launches and late stage trials will be under the microscope as eight European pharmaceuticals companies report Q1 earnings starting next week.
Sales grew 29.7% in a year marked by acquisitions and new products, while comparable operations sales grew 3.2%.
Ultragenyx, together with Kyowa Hakko Kirin and Kyowa Kirin International, on Tuesday unveiled 24-week data from a phase three study of burosumab in adults.